AstraZeneca and Oxford University will resume testing for counter vaccine COVID-19

On September 8th, tests for this vaccine were suspended after a volunteer from the United Kingdom deteriorated health, reports the BBC. AstraZenaca later said he would investigate whether worsening volunteer health was the side effect of the vaccine this company is developing.

This university said it's “which some participants in the research being conducted for the “vaccine can be sick”.

British authorities said tests will continue and will be followed by recommendations from an independent security committee, operating within the framework of the United Kingdom's Bar and Health Products Regulatory Agency.

Although patients ' diseases are confidential in the United Kingdom and are not published, the New York Times reported that a volunteer from the United Kingdom was diagnosed with an inflammatory sync that affects the spinal cord and may be caused by viral infections.

The vaccine, under way by AstraZeneca and Britain's Oxford University, is one of the most promising projects in the fight against COVID-19.

AstraZeneca is one of three companies that have arrived in the third phase of test of coronary vaccines in the United States, since thousands of volunteers have been provided there for the vaccine.

The other two vaccines are being developed by Pfizer and Moderna companies.

The World Health Organization says that in the world, about 180 potential vaccines against coronary are currently being tested.